Canada’s Drug Agency reverses course, now recommends public drug plans cover Alzheimer’s drug
Global - North America
•
July 16, 2026
•
0 Views
Federal agency says antibody medication lecanemab, which can slow cognitive decline, should be publicly reimbursed with conditions
Source: https://www.theglobeandmail.com/arc/outboundfeeds/rss/category/canada/ - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!



